Hidden

Type 2 Diabetes

MARKET POTENTIAL FOR AN INTRAVAGINAL RING FOR THE TREATMENT OF TYPE II DIABETES

-Approximately 12.6 million or 10.8% of all American women aged 20 years or older have diabetes. GLP-1 agonists such as exenatide are very valuable tools in the treatment of diabetes. Currently, these drugs are administered as daily or weekly injections. Many women do not prefer injections which leads to non-compliance and eventually, higher healthcare costs. 

-Based on several analyst reports, we believe that the GLP-1 agonist market is greater than $4 billion in annual sales. 

-Auritec Pharmaceuticals has formulated a GLP-1 agonist intravaginal ring (IVR) which may improve compliance and ease of use in Type II Diabetic women. This IVR has been tested in vitro and in vivo and has shown sustained-release for 2-4 weeks. It is being further developed for a first-in-human clinical trial

SURVEY RESULTS COMPARING WOMEN’S PREFERENCE FOR INTRAVAGINAL RINGS V/S INJECTIONS FOR TYPE 2 DIABETES

-In order to evaluate the potential market acceptance of a once-a-month intravaginal ring, in July 2015, we performed a research study with 51 Type II Diabetic women to understand their opinions on the acceptability of an exenatide intravaginal ring. 

-Twenty-six women (51%) women chose intravaginal rings over injections

-Sixteen of the 25 women that preferred daily or weekly injections chose this option because of their lack of experience with any vaginal rings. This indicates that patient education could further increase market penetration.